Future studies should investigate JAK1-selective inhibitors, such as upadacitinib and filgotinib, to provide a more comprehensive understanding of how different JAKi modulate IFN-γ signature genes in various clinical contexts, including patients with refractory RA. Here, IFNG is linked to rheumatoid arthritis.